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Newer Therapies in Hypercalcemia and Metabolic Bone Disease
Hunter Heath HI, MD*

T

he decade ofthe '80s has been an exciting one for all investigators in the area of calcium and bone metabolism because a
remarkable convergence of technology, basic science applications, and clinical interest has led to major advances in understanding this area. The physiology of calcium-regulating hormone secretion and action, mechanisms of plasma calcium
homeostasis, the cellular basis of metabolic bone disease—all
have yielded to concerted attack. However, the practicing physician has seen much of this advance somewhat from the sidelines,
asking legitimately when this new information was going to be
translated into practical measures for care of patients. This session was intended to address this justified query and to point out
several important therapeutic maneuvers that are available now,
are about to see general use, or represent promising first approaches to new agents. We focused on three important areas:
the life-threatening hypercalcemia frequently accompanying
malignant tumors, aluminum-related renal osteodystrophy,
and osteoporosis.

Hypercalcemia of Malignancy
The pathogenesis of hypercalcemia in malignancy is complex
and varies among tumor types. The older classification as "ectopic parathyroid hormone (PTH)-secreting" versus that caused
by direct tumor destmction of bone was based on indirect and
largely mistaken premises. Secretion of authentic PTH by nonparathyroid tumors has never been convincingly demonstrated,
and tumor metastases are now known to destroy bone indirectly,
by stimulating generation and activity of osteoclasts.
It is now clear that almost all nonparathyroidal malignant
tumors causing hypercalcemia do so by secreting or inducing
the formation of factors that in turn stimulate osteoclasts. One
such tumor product is a 141-amino acid peptide with some PTHlike structure and bioactivities. This PTH-related peptide (PTHrP) lyses bone but also stimulates renal tubular reabsorption of calcium; these two actions may account for the
viciousness of the ensuing hypercalcemia. Other direct or indirect tumor hypercalcemic substances may include 1,25dihydroxyvitamin D, prostaglandins, transforming growth
factors, and other peptide cytokines.
Diphosphonate treatment of severe hypercalcemia
Aside from various antitumor measures, there are no effective
ways to inhibit secretion of hypercalcemic factors. Thus, treatment ofthe hypercalcemia has focused first on inhibition of osteoclasts and second on enhancing renal excretion of calcium.
Body (1) reviewed agents currently available, then concentrated
on the biphosphonates (diphosphonates). These synthetic ana-

168

Henry Ford Hosp Med J—Vol 36, No 3, 1988

logs of pyrophosphate are potent inhibitors of bone resorption
but have varying potencies and mechanisms of action. They are
effective against the osteolytic component of hypercalcemia,
but do not alter renal tubular reabsorption of calcium, and therefore are relatively ineffective when the latter is a major causative factor.
The only bipbosphonate currently approved and on sale in the
United States is also the least useful in hypercalcemia: etidronate (EHDP) or Didronel®. It is ineffective against hypercalcemia when given orally but is effective intravenously. Several other biphosphonates have had considerable testing in
Europe and generally seem to be more effective than etidronate.
For example, clodronate (dichloromethylene bipbosphonate) at
100 to 300 mg/day for up to ten days can restore normocalcemia
in up to 90% of cases. However, relapse may occur rapidly after
discontinuance of clodronate. Amidronate (APD) (or AHPr BP)
is very effective when given as two-hour infusions of 15 mg/day
for up to 10 days. Doses less than 0.25 mg/kg/day are ineffective. This dmg is efficacious whether or not skeletal metastases
are present. Importantly, normocalcemia may last for several
weeks after stopping amidronate, and its toxicity is low, including transient fever and lymphopenia.
Still newer biphosphonates of even greater potency than
amidronate are being tested abroad, and some of them are being
tested in clinical trials in the United States. It seems likely that
within a few years we shall have available extremely potent biphosphonates capable of inducing prolonged normocalcemia in
cancer patients, and some of these agents may be active orally. It
is possible that these agents could also reverse or prevent skeletal destmction by metastases.
Potential use of gallium nitrate and WR-2721 in the
treatment of hypercalcemia and hyperparathyroidism
Bonjour et al (2) discussed two antihypercalcemic agents that
are much further from general use than the biphosphonates; gallium nitrate, and WR-2721 (an organic thiophosphate).
Gallium nitrate has been used for scanning bone and tumors,
but because of its localization in nonskeletal malignancies, it
saw further development as a chemotherapeutic agent. During
initial human studies, investigators occasionally saw transient
hypocalcemia, apparently caused by gallium nitrate. In vitro
studies indicated a direct effect of the compound on PTH- or
lymphokine-stimulated bone resorption, and further clinical in-
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vestigations suggested that it might be an effective antihypercalcemic agent in various types of malignancies. A recent, randomized, double-blind study suggested that gallium nitrate is
effective in lowering the hypercalcemia of malignancy and that
it may be superior to maximally effective doses of calcitonin.
The clinical use of gallium nitrate is not yet at hand, because
proper comparative studies versus other agents, such as methramycin and the biphosphonates, are not yet available. Further
studies are also needed to better understand gallium nitrate's
mechanisms of action. The existing data suggest that gallium nitrate or compounds derived therefrom may be very effective in
the acute treatment of humoral hypercalcemia of malignancy.
WR-2721 was also developed as a potential cancer therapeutic
agent to increase the resistance of normal tissues to ionizing
radiation and alkylating chemotherapeutic agents. Just as
for gallium nitrate, the hypocalcemic action of WR-2721 was
noted incidentally during phase I clinical trials. WR-2721 is a
remarkable compound in that it both decreases the secretion of
PTH in vitro and in vivo and directly inhibits renal tubular reabsorption of calcium. Furthermore, WR-2721 may directly inhibit osteoclastic bone resorption. Some evidence suggests that
WR-2721 is less potent than biphosphonates or gallium nitrate,
but more clinical studies are necessary. It is not yet clear
whether WR-2721 can inhibit secretion of the PTH-related peptide from tumors, but if it can it would have remarkable triple
efficacy in treating the humoral hypercalcemia of malignancy.
Just as for gallium nitrate, the very fact that WR-2721 has its
known effects greatly encourages the search for related compounds that may be highly effective in treating hypercalcemia of
multiple causes.

Aluminum-Associated Renal Osteodystrophy
Therapy of aluminum-related bone disease
Malluche and Faugere (3) described the syndromes of bone
disease related to skeletal aluminum accumulation that can occur in patients undergoing chronic hemodialysis. The aluminum
is ingested as aluminum hydroxide-containing phosphate-binding antacid gels or enters from contaminated dialysis solutions.
Excess bone aluminum may be demonstrable in nearly half of
patients on chronic dialysis and can occur even in mild to moderate renal failure. In particular, stainable aluminum gathers at the
interface between unmineralized bone matrix (osteoid) and mineralized bone, and it appears to impair the mineralization process. Clinical manifestations of aluminum-associated bone disease include bone pain, fractures, and hypercalcemia. The latter
must be carefuly differentiated from the hypercalcemia of "tertiary" hyperparathyroidism, because parathyroidectomy may
only aggravate aluminum-associated bone disease.
Malluche and Faugere (3) discussed chelation therapy with
the iron-binder, deferoxamine (Desferal®), which also binds
aluminum. Deferoxamine binds circulating aluminum ion,
which is then removed during dialysis. The lowered plasma aluminum level reverses the blood-bone concentration gradient,
and thus allows aluminum to diffuse out of bone. Important
reductions in bone aluminum can follow several months
of treatment.
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The histologic manifestations of aluminum-associated bone
disease vary from so-called "aplastic" or adynamic bone (no active bone formation or resorption, and no excess osteoid) to
florid osteomalacia. In all cases he has treated, Dr. Malluche
thought that aluminum chelation yielded improvement,
although reminding us that whatever other type of renal
osteodystrophy preceded or accompanied the aluminum accumulation would remain or emerge.
Deferoxamine therapy has serious side effects, potentially including hypotension, angina, and ocular damage. Because of
this and the difficulties in selecting cases for chelation therapy,
the treatment is best undertaken only after appropriate studies on
iliac crest bone biopsies and consultation with a nephrologist experienced in use of the drag. More long-term studies are needed
to establish firmly the safety and effectiveness of deferoxamine
in renal osteodystrophy.

Osteoporosis
Of all problems related to bone and calcium metabolism, the
clinical and economic impact of late-life and postmenopausal
osteoporosis is the greatest. While acute care of hip fracture
alone costs several billion dollars per year in the United States,
the worldwide cost in human suffering and national resources is
incalculable. While we have made dramatic progress toward understanding the causes of bone loss, physicians have been fmstrated by the few treatment options available. In particular, they
are impatient with the lack of treatments to increase bone mass,
rather than just slow its loss. In this part of the session, we
focused on new ways to deliver old treatments (transdermal estrogen) and preliminary reports on efficacy of two methods to
increase bone mass (fluoride and PTH).
New methods of administration of estrogens
Lindsay (4) outlined trends in estrogen prescription over recent years and highlighted controversies overrisksand benefits
of estrogen treatment after the menopause. Estrogen clearly retards or even stops bone loss after the menopause but increases
bone mass little if at all. Estrogen therapy may also decrease the
risk of cardiovascular disease, but on the other hand theriskof
endometrial carcinoma is increased. While simultaneous use of
a progestin, with endometrial shedding, seems to eliminate that
risk, the relative effects on cardiovascular risk and bone mass
remain unclear.
Similarly, delivery of estrogen transdermally bypasses the
liver and reduces certain estrogen effects mediated by the liver
(eg, increased plasma binding proteins and clotting factors). It is
not yet known if transdermal estrogen is cardioprotective or if its
salutary effect on bone equals that of oral estrogen. Trials in osteoporosis are under way, but it will be a long time before all the
answers are in on how best to give estrogen, to whom, and for
how long. The transdermal route for estrogen is likely to be
available soon as a treatment altemative.
The role of sodiumfluoridein the treatment of osteoporosis
Current studies with sodiumfluoride(NaF) were summarized
by Riggs et al (5). It has been known for many years that skeletal
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fluorosis can result in sclerotic bones, but only over the last five
years have there been two long-term, placebo-controlled trials
of NaF in established osteoporosis, one at the Mayo Clinic, and
one at Henry Ford Hospital. The authors described preliminary
data from the Mayo study, which is nearing completion. In brief,
more than half of the patients taking NaF have had increased
lumbar spine bone mineral density, but NaF had no effect at all
on appendicular (cortical) bone mass. The drag therefore may
be of benefit only to those primarily suffering from the crash
fracture syndrome. Furthermore, there was a significant minority who did not respond to NaF, and the treatment was associated
with a fairly high incidence of various side effects, including
gastric irritation and bleeding, anemia, and lower-extremity
pain from stress fractures. Data on fracture rates are still being
obtained. Obviously, antifracture efficacy of NaF must be determined before it can be approved for general use. Because the
bone generated during NaF treatment is stractually abnormal, it
is possible (but unlikely) that the increased bone mass would not
stop fracturing. The bone community eagerly awaits definitive
reports from both of the large trials to see if NaF will find a major
role in treatment of osteoporosis.
Parathyroid peptide (hPTH 1-34) in the treatment of
osteoporosis
Reeve et al (6) gave an update on clinical trials with a seemingly paradoxical treatment for osteoporosis: parenteral synthetic PTH fragment 1-34 [hPTH-(l-34)]. In hyperparathyroid
diseases, endogenous PTH generally causes bone loss, but intermittent elevation of PTH in animals by injection sometimes
causes osteosclerosis. Reeve and colleagues have taken advantage of the fact that PTH can increase bone formation as well as
resorption. They have administered hPTH-(l-34) as once-daily
injections alone or in combination with 1,25-dihydroxyvitamin
D or estrogen. The latter compounds were given to enhance calcium absorption, which does not reliably follow intermittent
elevations of plasma PTH.
When daily hPTH-(l-34) was given alone, they saw increased
trabecular volume in iliac crest biopsies but neutral calcium balance and decreased femoral bone mass. In early studies, alternating hPTH-(l-34) for six weeks with 1,25-dihydroxyvitamin
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D for six weeks appeared to increase spinal bone mass, as did
combination of hPTH-(l-34) with estrogen.
This work is important for what it teaches about physiology of
bone, but application of hPTH-(l-34) to clinical practice in these
complex regimens is problematic. The peptide is very expensive
and must be given parenterally. Further, the difficulty in finding
a simple, safe, and effective regimen is somewhat discouraging.
At a minimum, this work shows that bone formation can be
increased by something other than fluoride and certainly will
encourage continued research.

Final Note
This session showed that safe, effective acute therapy for lifethreatening hypercalcemia is now available and will soon be
even better, that altemative methods for administering estrogen
will soon be out, and that effective treatments to increase bone
mass (at least in the spine) are feasible and may reach clinical
use within the next five years. If advances in the coming decade
match those of the last, it may not be too mucb to hope that death
and morbidity from several bone and calcium disorders could be
virtually eliminated before the end of the century.
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